Award details

Evaluating adenoviral adeno-associated viral and non-primate lentiviral vectors as gene therapy agents in the arginine-vasopressin deficient Brattleboro rat

Reference	GTH12528
Principal Investigator / Supervisor	Professor James Uney
Co-Investigators / Co-Supervisors	Dr Harry Charlton, Professor Stafford Lightman
Institution	University of Bristol
Department	Physiology and Pharmacology
Funding type	Research
Value (£)	324,184
Status	Completed
Type	Research Grant
Start date	01/05/2000
End date	07/08/2003
Duration	39 months

Abstract

The hypothesis is that it is not possible to use newly developed gutless adenoviral, adeno- associated viral and lentiviral vectors as effective gene therapy agents in the CNS. To test this hypothesis viral vectors expressing arginine vasopressin (AVP) gene constructs will be transfected into the hypothalamus of the AVP- deficient Brattleboro rat. This model will allow us to assess: (1), the success of the gene therapy treatment by non- invasive assays; (2), the immune response generated following injection of the viral vectors, (3) whether the AVP gene is sensitive to normal physiological regulation when its expression is mediated from a viral vector.

Summary

unavailable

Committee	Closed Committee - Genes & Developmental Biology (GDB)
Research Topics	X – not assigned to a current Research Topic
Research Priority	X – Research Priority information not available
Research Initiative	Gene Technologies Underpinning Healthcare (GTH) [1999]
Funding Scheme	X – not Funded via a specific Funding Scheme

I accept the terms and conditions of use (opens in new window)

export PDF file

back to list new search